Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Recommendation of “Buy” from Brokerages

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has received a consensus recommendation of “Buy” from the eight analysts that are covering the stock, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $20.83.

ZVRA has been the topic of a number of recent analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zevra Therapeutics in a research report on Friday. William Blair upgraded Zevra Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Zevra Therapeutics in a research report on Monday, September 30th. Guggenheim initiated coverage on Zevra Therapeutics in a research report on Monday, October 7th. They issued a “buy” rating and a $20.00 target price on the stock. Finally, JMP Securities initiated coverage on Zevra Therapeutics in a research report on Tuesday, September 24th. They issued an “outperform” rating and a $17.00 target price on the stock.

Insiders Place Their Bets

In other Zevra Therapeutics news, Director Thomas Anderson bought 10,000 shares of the stock in a transaction on Tuesday, July 16th. The stock was acquired at an average cost of $6.81 per share, for a total transaction of $68,100.00. Following the completion of the acquisition, the director now owns 20,000 shares in the company, valued at $136,200. This trade represents a 100.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link. 2.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Zevra Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. City State Bank increased its holdings in shares of Zevra Therapeutics by 14.1% during the third quarter. City State Bank now owns 16,224 shares of the company’s stock valued at $113,000 after acquiring an additional 2,000 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Zevra Therapeutics during the third quarter valued at approximately $105,000. Sanctuary Advisors LLC bought a new stake in Zevra Therapeutics during the second quarter worth $474,000. The Manufacturers Life Insurance Company grew its holdings in Zevra Therapeutics by 15.2% during the second quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock worth $91,000 after buying an additional 2,452 shares in the last quarter. Finally, Retirement Planning Co of New England Inc. grew its holdings in Zevra Therapeutics by 6.5% during the second quarter. Retirement Planning Co of New England Inc. now owns 458,300 shares of the company’s stock worth $2,246,000 after buying an additional 28,107 shares in the last quarter. Institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Stock Up 3.0 %

Shares of NASDAQ ZVRA opened at $8.16 on Friday. The company has a debt-to-equity ratio of 1.80, a quick ratio of 2.00 and a current ratio of 2.00. Zevra Therapeutics has a 52 week low of $3.89 and a 52 week high of $8.95. The stock has a market capitalization of $429.38 million, a P/E ratio of -4.86 and a beta of 1.94. The stock’s fifty day moving average is $7.44 and its 200 day moving average is $5.87.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). Zevra Therapeutics had a negative return on equity of 124.85% and a negative net margin of 274.10%. The company had revenue of $4.45 million during the quarter, compared to the consensus estimate of $4.08 million. During the same quarter in the previous year, the business posted ($0.15) EPS. Sell-side analysts forecast that Zevra Therapeutics will post -1.63 earnings per share for the current fiscal year.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.